Literature DB >> 20049532

Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5'-phosphate availability.

Shanti Balasubramaniam1, Frank Bowling, Kevin Carpenter, John Earl, Jeffrey Chaitow, James Pitt, Etienne Mornet, David Sillence, Carolyn Ellaway.   

Abstract

We describe two neonates presenting with perinatal hypophosphatasia and severe epileptic encephalopathy resulting in death. Both had increased levels of urinary vanillactate, indicating functional deficiency of aromatic amino acid decarboxylase, a pyridoxal-5-phosphate (PLP)-dependent enzyme required for dopamine and serotonin biosynthesis. Clinical findings and results of subsequent metabolic investigations were consistent with secondary pyridoxine-deficient encephalopathy. These patients highlight the importance of tissue non-specific alkaline phosphatase in the neuronal PLP-dependent metabolism of neurotransmitters. In addition, the disturbance of PLP metabolism appears to underlie the predominant neurological presentation in our patients. We recommend the measurement of serum alkaline phosphatase (ALP) during the assessment of perinatal seizures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049532     DOI: 10.1007/s10545-009-9012-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  28 in total

1.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

Review 2.  Alkaline phosphatase: a potential biomarker for stroke and implications for treatment.

Authors:  Allison L Brichacek; Candice M Brown
Journal:  Metab Brain Dis       Date:  2018-10-04       Impact factor: 3.584

3.  Infantile hypophosphatasia secondary to a novel compound heterozygous mutation presenting with pyridoxine-responsive seizures.

Authors:  Dina Belachew; Traci Kazmerski; Ingrid Libman; Amy C Goldstein; Susan T Stevens; Stephanie Deward; Jerry Vockley; Mark A Sperling; Arcangela L Balest
Journal:  JIMD Rep       Date:  2013-03-12

Review 4.  Hypophosphatasia: Biological and Clinical Aspects, Avenues for Therapy.

Authors:  Jean Pierre Salles
Journal:  Clin Biochem Rev       Date:  2020-02

Review 5.  Hypophosphatasia: an overview of the disease and its treatment.

Authors:  M L Bianchi
Journal:  Osteoporos Int       Date:  2015-08-06       Impact factor: 4.507

6.  Systemic Manifestations in Pyridox(am)ine 5'-Phosphate Oxidase Deficiency.

Authors:  Réjean M Guerriero; Archana A Patel; Brian Walsh; Fiona M Baumer; Ankoor S Shah; Jurriaan M Peters; Lance H Rodan; Pankaj B Agrawal; Phillip L Pearl; Masanori Takeoka
Journal:  Pediatr Neurol       Date:  2017-06-03       Impact factor: 3.372

Review 7.  Hypophosphatasia: From Diagnosis to Treatment.

Authors:  Sebastian Simon; Heinrich Resch; Klaus Klaushofer; Paul Roschger; Jochen Zwerina; Roland Kocijan
Journal:  Curr Rheumatol Rep       Date:  2018-09-10       Impact factor: 4.592

8.  Ablation of TNAP function compromises myelination and synaptogenesis in the mouse brain.

Authors:  János Hanics; János Barna; Jinsong Xiao; José Luis Millán; Caroline Fonta; László Négyessy
Journal:  Cell Tissue Res       Date:  2012-06-14       Impact factor: 5.249

9.  Identification of altered brain metabolites associated with TNAP activity in a mouse model of hypophosphatasia using untargeted NMR-based metabolomics analysis.

Authors:  Thomas Cruz; Marie Gleizes; Stéphane Balayssac; Etienne Mornet; Grégory Marsal; José Luis Millán; Myriam Malet-Martino; Lionel G Nowak; Véronique Gilard; Caroline Fonta
Journal:  J Neurochem       Date:  2017-03       Impact factor: 5.372

10.  Diagnosis of Hypophosphatasia in Adults Presenting With Metatarsal Stress Fracture: Proof-of-Concept for a Case-Finding Strategy.

Authors:  Kenna Koehler; Said Atway; James Pipes; Steven Ing
Journal:  JBMR Plus       Date:  2021-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.